600161 天坛生物
已收盘 02-06 15:00:00
资讯
新帖
简况
每周股票复盘:天坛生物(600161)审计机构变更项目质量复核人
证券之星 · 01:40
每周股票复盘:天坛生物(600161)审计机构变更项目质量复核人
天坛生物(600161)披露审计机构变更项目质量复核人公告,2月4日股价上涨0.49%
证券之星 · 02-04
天坛生物(600161)披露审计机构变更项目质量复核人公告,2月4日股价上涨0.49%
每周股票复盘:天坛生物(600161)董事长变更为梁红军
证券之星 · 01-18
每周股票复盘:天坛生物(600161)董事长变更为梁红军
天坛生物(600161)公司公告董事长离任,1月16日股价下跌1.35%
证券之星 · 01-16
天坛生物(600161)公司公告董事长离任,1月16日股价下跌1.35%
天坛生物最新公告:董事长杨汇川因工作调整辞职
证券之星 · 01-16
天坛生物最新公告:董事长杨汇川因工作调整辞职
每周股票复盘:天坛生物(600161)2026年预计关联交易总额超17亿元
证券之星 · 01-11
每周股票复盘:天坛生物(600161)2026年预计关联交易总额超17亿元
天坛生物(600161)披露增补董事及2026年度日常关联交易预计事项,1月9日股价上涨0.83%
证券之星 · 01-09
天坛生物(600161)披露增补董事及2026年度日常关联交易预计事项,1月9日股价上涨0.83%
每周股票复盘:天坛生物(600161)拟增投浆站及生产项目
证券之星 · 01-02
每周股票复盘:天坛生物(600161)拟增投浆站及生产项目
天坛生物(600161)披露召开2026年第一次临时股东会通知,12月31日股价下跌0.73%
证券之星 · 2025-12-31
天坛生物(600161)披露召开2026年第一次临时股东会通知,12月31日股价下跌0.73%
天坛生物董事张洁明离任
北京商报 · 2025-12-31
天坛生物董事张洁明离任
股市必读:天坛生物(600161)今年截至12月23日累计跌幅已超20%
证券之星 · 2025-12-24
股市必读:天坛生物(600161)今年截至12月23日累计跌幅已超20%
天坛生物旗下成都蓉生重组八因子新药启动III期临床
中金财经 · 2025-12-20
天坛生物旗下成都蓉生重组八因子新药启动III期临床
天坛生物(600161)披露下属企业药品临床试验进展,12月19日股价上涨0.86%
证券之星 · 2025-12-19
天坛生物(600161)披露下属企业药品临床试验进展,12月19日股价上涨0.86%
12月12日天坛生物现1笔大宗交易 机构净卖出381.21万元
证券之星 · 2025-12-12
12月12日天坛生物现1笔大宗交易 机构净卖出381.21万元
天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%
证券之星 · 2025-12-04
天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%
天坛生物(600161.SH)下属企业获得临床试验总结报告
智通财经 · 2025-12-04
天坛生物(600161.SH)下属企业获得临床试验总结报告
天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%
证券之星 · 2025-11-24
天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%
每周股票复盘:天坛生物(600161)现2751万元大宗交易
证券之星 · 2025-11-23
每周股票复盘:天坛生物(600161)现2751万元大宗交易
天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请
智通财经 · 2025-11-19
天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请
每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易
证券之星 · 2025-11-09
每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易
加载更多
公司概况
公司名称:
北京天坛生物制品股份有限公司
所属行业:
医药制造业
上市日期:
1998-06-16
主营业务:
北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。
发行价格:
4.07
{"stockData":{"symbol":"600161","market":"SH","secType":"STK","nameCN":"天坛生物","latestPrice":16.53,"timestamp":1770361200000,"preClose":16.65,"halted":0,"volume":6476604,"delay":0,"changeRate":-0.0072,"floatShares":1977000000,"shares":1977000000,"eps":0.6656,"marketStatus":"已收盘","change":-0.12,"latestTime":"02-06 15:00:00","open":16.64,"high":16.67,"low":16.52,"amount":107000000,"amplitude":0.009,"askPrice":16.53,"askSize":680,"bidPrice":16.52,"bidSize":2337,"shortable":0,"etf":0,"ttmEps":0.6656,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.65,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":18.32,"lowLimit":14.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1977371446,"isCdr":false,"pbRate":2.85,"roa":"--","peRate":24.834736,"roe":"7.16%","epsLYR":0.78,"committee":0.550279,"marketValue":32686000000,"turnoverRate":0.0033,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-02-09。","floatMarketCap":32686000000},"requestUrl":"/m/hq/s/600161","defaultTab":"news","newsList":[{"id":"2609525892","title":"每周股票复盘:天坛生物(600161)审计机构变更项目质量复核人","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525892?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:40","pubTimestamp":1770486023,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,天坛生物报收于16.53元,较上周的16.65元下跌0.72%。本周关注点来自公司公告汇总:天坛生物变更2025年度审计项目质量复核人,黄加才接替韦军。公司公告汇总天坛生物关于审计机构变更项目质量复核人的公告北京天坛生物制品股份有限公司于2026年2月4日发布公告,因天健会计师事务所原项目质量复核人韦军先生工作调整,现委派黄加才先生接替其职务,担任公司2025年度财务报表及内部控制审计项目的质量复核人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","BK0239","BK0185","600161","BK0188","BK0082","BK0168","BK0046"],"gpt_icon":0},{"id":"2608080360","title":"天坛生物(600161)披露审计机构变更项目质量复核人公告,2月4日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608080360","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608080360?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:20","pubTimestamp":1770214830,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,天坛生物报收于16.5元,较前一交易日上涨0.49%,最新总市值为326.27亿元。该股当日开盘16.41元,最高16.5元,最低16.33元,成交额达1.29亿元,换手率为0.4%。近日,天坛生物发布《关于审计机构变更项目质量复核人的公告》。公告显示,因天健会计师事务所原项目质量复核人韦军先生工作调整,公司2025年度财务报表及内部控制审计项目的质量复核人变更为黄加才先生。公告指出,本次变更已有序交接,不会对公司审计工作产生不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600161","BK0185","BK0046","BK0010","BK0168","BK0028","BK0239","BK0082"],"gpt_icon":0},{"id":"2604792300","title":"每周股票复盘:天坛生物(600161)董事长变更为梁红军","url":"https://stock-news.laohu8.com/highlight/detail?id=2604792300","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604792300?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:32","pubTimestamp":1768678329,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,天坛生物报收于16.85元,较上周的17.05元下跌1.17%。本周关注点公司公告汇总:天坛生物选举梁红军为新任董事长,并通过2026年度日常关联交易预计议案。关联交易议案获同意票85.3861%,关联股东中国生物技术股份有限公司回避表决;增补董事议案得票占出席会议有效表决权的98.6613%,梁红军当选生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0239","BK0046","BK0185","BK0082","BK0028","BK0188","BK0010","600161"],"gpt_icon":0},{"id":"2603994105","title":"天坛生物(600161)公司公告董事长离任,1月16日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994105","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994105?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:38","pubTimestamp":1768574295,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,天坛生物报收于16.85元,较前一交易日下跌1.35%,最新总市值为333.19亿元。该股当日开盘17.1元,最高17.16元,最低16.82元,成交额达1.87亿元,换手率为0.56%。近日,天坛生物发布公告称,公司董事长杨汇川因工作调整,于2026年1月16日辞去董事长、董事会战略与投资委员会主任委员、董事会业绩考核与薪酬委员会委员、董事会提名委员会委员职务。辞职后,杨汇川继续担任公司董事、总经理职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0239","BK0046","BK0185","BK0082","BK0028","BK0188","BK0010","600161"],"gpt_icon":0},{"id":"2603153996","title":"天坛生物最新公告:董事长杨汇川因工作调整辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2603153996","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603153996?lang=zh_cn&edition=full","pubTime":"2026-01-16 21:09","pubTimestamp":1768568991,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司董事长杨汇川因工作调整原因,向董事会递交书面辞职报告,辞去包括董事长在内的多个职务。辞职后,杨汇川将继续担任公司董事、总经理。其直接持有的46,800股股份占公司总股比的0.0024%,将继续遵守增持承诺。同时,公司选举梁红军为新任董事长。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600039505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0046","BK0239","600161","BK0010","BK0082","BK0028","BK0168","BK0188"],"gpt_icon":0},{"id":"2602539856","title":"每周股票复盘:天坛生物(600161)2026年预计关联交易总额超17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602539856?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:25","pubTimestamp":1768076708,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,天坛生物报收于17.05元,较上周的16.34元上涨4.35%。本周,天坛生物1月9日盘中最高价报17.12元。2026年预计购销商品、接受及提供劳务关联交易额为172,359.86万元,租赁关联交易额为3,872.34万元,在关联财务公司存款日最高额不超过450,000.00万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0082","600161","BK0239","BK0168","BK0010","BK0185","BK0188","BK0028"],"gpt_icon":0},{"id":"2602726893","title":"天坛生物(600161)披露增补董事及2026年度日常关联交易预计事项,1月9日股价上涨0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602726893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602726893?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:53","pubTimestamp":1767970389,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,天坛生物报收于17.05元,较前一交易日上涨0.83%,最新总市值为337.14亿元。近日,天坛生物发布关于召开2026年第一次临时股东会的会议文件,披露了两项重要议案。其中一项为增补梁红军为公司第九届董事会董事;另一项涉及2026年度日常关联交易预计事项。根据公告,2026年公司预计发生购销商品、接受及提供劳务类关联交易金额为172,359.86万元,租赁类关联交易金额为3,872.34万元,在关联财务公司存款日最高余额不超过450,000.00万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0028","600161","BK0168","BK0185","BK0188","BK0046","BK0239"],"gpt_icon":0},{"id":"2600703500","title":"每周股票复盘:天坛生物(600161)拟增投浆站及生产项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2600703500","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600703500?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:28","pubTimestamp":1767292091,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,天坛生物报收于16.68元,较上周的16.44元上涨1.46%。其中,日常关联交易议案涉及关联股东回避表决,中国生物技术股份有限公司及其子公司需回避。公司董事张洁明因工作调整原因,于2025年12月31日辞去董事职务,原定任期至2026年5月24日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0168","BK0046","BK0185","BK0028","600161","BK0010","BK0239","BK0188"],"gpt_icon":0},{"id":"2595777837","title":"天坛生物(600161)披露召开2026年第一次临时股东会通知,12月31日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777837?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:14","pubTimestamp":1767190456,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,天坛生物报收于16.34元,较前一交易日下跌0.73%,最新总市值为323.1亿元。近日,天坛生物发布关于召开2026年第一次临时股东会的通知。公告显示,北京天坛生物制品股份有限公司将于2026年1月16日召开2026年第一次临时股东会,会议采取现场投票与网络投票相结合的方式,股权登记日为2026年1月9日。其中,日常关联交易议案涉及关联股东回避表决,中国生物技术股份有限公司及其子公司需回避。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0168","BK0185","BK0028","BK0046","BK0188","BK0082","BK0010","600161"],"gpt_icon":0},{"id":"2595277534","title":"天坛生物董事张洁明离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2595277534","media":"北京商报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595277534?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:38","pubTimestamp":1767177480,"startTime":"0","endTime":"0","summary":"北京商报讯12月31日,天坛生物发布公告称,张洁明因工作调整原因辞去公司董事职务,原定任期到期日为2026年5月24日。离任后,张洁明不再在公司及其控股子公司任职。 同时,天坛生物召开董事会会议,同意提名梁红军为公司第九届董事会董事,任期至第九届董事会换届。(文章来源:北京商报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-31/doc-inhesxnh8996918.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-31/doc-inhesxnh8996918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0185","BK0046","600161","BK0010","BK0239","BK0082","BK0028","BK0188","BK0168"],"gpt_icon":0},{"id":"2593414166","title":"股市必读:天坛生物(600161)今年截至12月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593414166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593414166?lang=zh_cn&edition=full","pubTime":"2025-12-24 01:13","pubTimestamp":1766509992,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘,天坛生物报收于16.13元,下跌1.95%,换手率0.58%,成交量11.48万手,成交额1.86亿元。交易信息汇总股价提醒12月23日天坛生物收盘报16.13元,跌1.95%,当日成交1148.19万元。根据收盘数据统计,该股当年累计跌幅20.26%。前10个交易日资金流向情况:主力资金累计净流出8128.28万元,股价累计下跌4.94%;融资余额累计增加1147.5万元,融券余量累计减少3.19万股。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400000624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","600161","BK0010","BK0082","BK0188","BK0168","BK0028","BK0185","BK0239"],"gpt_icon":0},{"id":"2592811181","title":"天坛生物旗下成都蓉生重组八因子新药启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2592811181","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592811181?lang=zh_cn&edition=full","pubTime":"2025-12-20 10:42","pubTimestamp":1766198535,"startTime":"0","endTime":"0","summary":"中访网数据 北京天坛生物制品股份有限公司今日公告,其下属企业成都蓉生药业有限责任公司研发的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”已于近日正式启动III期临床试验。该药品注册分类为治疗用生物制品,拟用于A型血友病患者的出血控制、预防及手术出血预防。根据公告,该产品研发累计投入已达9868.32万元。目前,国内市场尚无同类产品上市,国际市场主要有赛诺菲公司的Eloctate和Altuviiio两款产品。该药品后续仍需完成III期临床试验、提交上市申请并通过国家药监部门审评审批,方可实现上市销售。天坛生物提示,药品研发周期长且存在不确定性,投资者需注意相关风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251220/31879523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0046","BK0185","BK4134","III","BK0188","BK0239","600161","BK0168","BK0028","BK0082","BK0010"],"gpt_icon":0},{"id":"2592160737","title":"天坛生物(600161)披露下属企业药品临床试验进展,12月19日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160737","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592160737?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:19","pubTimestamp":1766153978,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,天坛生物报收于16.44元,较前一交易日上涨0.86%,最新总市值为325.08亿元。该股当日开盘16.29元,最高16.5元,最低16.28元,成交额达1.3亿元,换手率为0.4%。公司近日发布公告称,其下属成都蓉生药业有限责任公司研制的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”于近日正式开展Ⅲ期临床试验。该产品已获临床试验批准,规格为250IU/瓶和1000IU/瓶,研发投资9868.32万元。后续还需完成Ⅲ期临床试验、提交上市申请并经审评审批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0185","BK0046","600161","BK0082","BK0168","BK0239","BK0010"],"gpt_icon":0},{"id":"2590577510","title":"12月12日天坛生物现1笔大宗交易 机构净卖出381.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577510","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577510?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:57","pubTimestamp":1765533477,"startTime":"0","endTime":"0","summary":"证券之星消息,12月12日天坛生物发生大宗交易,交易数据如下:大宗交易成交价格16.34元,成交23.33万股,成交金额381.21万元,买方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部,卖方营业部为机构专用。近三个月该股共发生3笔大宗交易,合计成交2.93万手。截至2025年12月12日收盘,天坛生物报收于16.34元,下跌1.98%,换手率1.34%,成交量26.5万手,成交额4.34亿元。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0046","600161","BK0010","BK0188","BK0239","BK0028","BK0082","BK0168"],"gpt_icon":0},{"id":"2588809498","title":"天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588809498","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588809498?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:14","pubTimestamp":1764857666,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘,天坛生物报收于17.0元,较前一交易日下跌0.93%,最新总市值为336.15亿元。该股当日开盘17.16元,最高17.17元,最低16.99元,成交额达1.08亿元,换手率为0.32%。近日,天坛生物发布公告称,公司下属国药集团贵州生物制药有限公司研制的人凝血酶原复合物已完成Ⅲ期临床试验并取得临床试验总结报告。临床试验结果显示,该产品可显著提升凝血因子水平,改善出血症状,具有良好的安全性和有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0188","BK0028","BK0010","BK0046","BK0168","BK0239","BK0082","BK0185"],"gpt_icon":0},{"id":"2588007689","title":"天坛生物(600161.SH)下属企业获得临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2588007689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588007689?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:15","pubTimestamp":1764839718,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)发布公告,近日,公司下属国药集团贵州生物制药有限公司(简称“天坛贵州”)研制的“人凝血酶原复合物”完成了Ⅲ期临床试验并取得临床试验总结报告。天坛贵州生产的人凝血酶原复合物临床试验结果显示,输注后能显著提升血友病B患者的凝血因子Ⅱ/Ⅶ/Ⅸ/Ⅹ水平、提高血友病B患者的凝血功能,改善血友病B患者的出血症状和体征,对血友病B患者具有良好的疗效。同时安全性分析结果显示,该药物在临床应用过程中对血友病B患者具有良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0046","BK0188","600161","BK0168","BK0010","BK0082","BK0028","BK0239"],"gpt_icon":0},{"id":"2585604054","title":"天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585604054","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585604054?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993635,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,天坛生物报收于17.66元,较前一交易日上涨0.28%,最新总市值为349.2亿元。该事项已获实际控制人中国医药集团有限公司批复。本次划转完成后,中国生物将直接持有公司921,302,854股股份,占总股本46.59%,北京所不再持有公司股份。中国生物及其一致行动人合计持股数量和比例保持不变,均为991,120,289股、50.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0168","BK0046","BK0185","BK0010","BK0188","BK0239","BK0028","600161"],"gpt_icon":0},{"id":"2585103318","title":"每周股票复盘:天坛生物(600161)现2751万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103318?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:13","pubTimestamp":1763835191,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,天坛生物报收于17.61元,较上周的18.59元下跌5.27%。本周,天坛生物11月17日盘中最高价报18.62元。本周关注点交易信息汇总:11月17日天坛生物现2751万元大宗交易。交易信息汇总11月17日天坛生物现2751万元大宗交易公司公告汇总北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司研发的注射用重组人凝血因子Ⅶa,因需补充儿童患者群体临床试验数据,已向国家药品监督管理局药品审评中心提出撤回上市许可申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0185","BK0082","BK0188","BK0028","600161","BK0168","BK0046"],"gpt_icon":0},{"id":"2584791162","title":"天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2584791162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584791162?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:10","pubTimestamp":1763543409,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)发布公告,北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司(以下简称 “成都蓉生”)研发的“注射用重组人凝血因子Ⅶa”于2025年1月向国家药品监督管理局药品审评中心(CDE)递交上市许可申请,并获得《受理通知书》(受理号:CXSS2500005)。自获得该产品上市许可申请受理以来,成都蓉生持续开展配合审评相关工作。近日,根据CDE审评意见,该产品需补充儿童(<12岁)患者群体的临床试验相关数据。据此,成都蓉生向CDE提出了药品注册撤回申请,将在补充完善相关临床数据工作后,重新提交药品上市许可注册申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0046","600161","BK0028","BK0188","BK0010","BK0168","BK0239","BK0185"],"gpt_icon":0},{"id":"2582869654","title":"每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2582869654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582869654?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:40","pubTimestamp":1762627225,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,天坛生物报收于18.42元,较上周的18.43元下跌0.05%。本周,天坛生物11月4日盘中最高价报18.54元。11月3日盘中最低价报18.32元。天坛生物当前最新总市值364.23亿元,在生物制品板块市值排名9/51,在两市A股市值排名504/5166。投资者可于2025年11月5日至11月11日16:00前通过上证路演中心“提问预征集”栏目或公司投资者关系邮箱ttswdb@sinopharm.com提交问题。说明会期间,投资者可登录上证路演中心在线参与并提问。联系部门:董事会办公室;电话:010-65439720。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0010","BK0168","600161","BK0082","BK0185","BK0188","BK0239","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770565569684,"stockEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.1026},{"period":"6month","weight":-0.1845},{"period":"1year","weight":-0.2043},{"period":"ytd","weight":0.0116}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京天坛生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79044人(较上一季度增加1.50%)","perCapita":"25016股","listingDate":"1998-06-16","address":"北京市大兴区北京经济技术开发区博兴二路6号院8号楼521室","registeredCapital":"197737万元","survey":" 北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。","listedPrice":4.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天坛生物,600161,天坛生物股票,天坛生物股票老虎,天坛生物股票老虎国际,天坛生物行情,天坛生物股票行情,天坛生物股价,天坛生物股市,天坛生物股票价格,天坛生物股票交易,天坛生物股票购买,天坛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}